Contineum Therapeutics, Inc. (CTNM) vs REGENXBIO Inc. (RGNX)

Contineum Therapeutics, Inc. and REGENXBIO Inc. are both Biotechnology companies. Contineum Therapeutics, Inc. and REGENXBIO Inc. are of similar size ($487.8M and $469.9M). Contineum Therapeutics, Inc. has the higher net margin (0.00% vs −112.6%) and the lower return on invested capital (−1,334.4% vs 0.00%). Across the 12 metrics below, Contineum Therapeutics, Inc. leads on 9 and REGENXBIO Inc. on 3.

Valuation

Metric CTNM RGNX Biotechnology median
P/E n/m n/m 7.88
P/S n/m 2.24 11.47
P/B 1.96 5.45 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 2.12 10.73
Earnings yield (13.77%) (51.22%) (28.84%)
Free cash flow yield (11.36%) (63.88%) (23.03%)

Profitability

Metric CTNM RGNX Biotechnology median
Gross margin — 86.38% 65.16%
Operating margin 0.00% (94.08%) 0.00%
Net margin 0.00% (112.58%) 0.00%
Free cash flow margin 0.00% (143.09%) 0.00%
Return on equity (28.01%) (137.63%) (57.72%)
Return on assets (26.57%) (40.60%) (49.22%)
Return on invested capital (1,334.41%) 0.00% 0.00%

Growth

Metric CTNM RGNX Biotechnology median
Revenue growth (TTM) — 12.00% 5.64%
EPS growth (last fiscal year) 0.46% 18.08% —
Revenue growth, 5-year CAGR — 1.97% 8.40%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric CTNM RGNX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 37.17 2.86 4.73
Net debt to EBITDA 3.88 1.58 0.96

Dividend

Metric CTNM RGNX Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric CTNM RGNX Biotechnology median
Market cap 469.89m 487.84m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack